<DOC>
	<DOCNO>NCT01908816</DOCNO>
	<brief_summary>The pupose study evaluate safety efficacy ranibizumab rare VEGF driven ocular disease .</brief_summary>
	<brief_title>An Open-label Extended Clinical Protocol Ranibizumab Evaluate Safety Efficacy Rare VEGF Driven Ocular Diseases .</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Glaucoma , Neovascular</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Active choroidal neovascularization ( CNV ) Active macular edema ( ME ) Rubeosis iridis/neovascular glaucoma . Proliferative diabetic retinopathy require vitrectomy . wet Agerelated macular degeneration pathologic myopia pseudoxanthoma elasticum diabetic macular edema retinal vein occlusion &lt; 18 year age History hypersensitivity ranibizumab Use systemic antiangiogenic drug 3 month inclusion Women childbearing potential Pregnant nursing ( lactate ) woman . Active suspect ocular infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>